J&J Muscles Into CAR-T Field: Initiates Myeloma Studies
Executive Summary
An autologous CAR-T therapy in development by Janssen and Legend Biotech is expected to kick-off US clinical studies in the second half of 2018, adding to the race to apply the new technology to multiple myeloma.
You may also be interested in...
J&J, Flush With Cash, Has Flexibility To Be ‘Bolder’ On M&A, CEO Duato Says
The company kicked off the new year with a new CEO, plans to break out consumer health, and a strong financial position, including $32bn in cash and lowest level of net debt in more than four years.
Where Is J&J Investing For The Future? Cell Therapy, Gene Therapy And RNA
Janssen global head of R&D Mathai Mammen said the three areas are therapeutic modalities J&J is prioritizing for future drug development, both internally and through partnering.
ASH Preview: BCMA-Targeting CAR-Ts And Bispecifics Hog The Spotlight
Some of the most anticipated data at ASH are for therapies targeting BCMA in multiple myeloma, including a next-gen CAR-T from bluebird and Celgene as well as Amgen's novel BiTE, but an update from China's Legend Biotech and J&J could steal the show.